MedTrace Logo

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

NCT01134055 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 510

Last updated 2018-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.

Conditions

  • Macular Degeneration

Interventions

DRUG

pazopanib eye drops

A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.

DRUG

placebo

placebo eye drops

BIOLOGICAL

ranibizumab intravitreal injection

Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-01
Primary Completion
2012-10-01
Completion
2012-10-01

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Denmark
  • Germany
  • Italy
  • Japan
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01134055 on ClinicalTrials.gov